ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL553
CHEMBL553
Compound Name ERLOTINIB
ChEMBL Synonyms CP-358774-01 | RG-1415 | R-1415 | ERLOTINIB HYDROCHLORIDE | CP-358,774-01 | OSI-774 | TARCEVA | ERLOTINIB | Ro-508231 | CP-358774
Max Phase 4 (Approved)
Trade Names TARCEVA | ERLOTINIB HYDROCHLORIDE
Molecular Formula C22H23N3O4

Additional synonyms for CHEMBL553 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC
Standard InChI InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28 ...
Download InChI
Standard InChI Key AAKJLRGGTJKAMG-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • BindingDB Database
  • British National Formulary
  • DrugMatrix
  • Orange Book
  • Patent Bioactivity Data
  • PubChem BioAssays
  • Sanger Institute Genomics of Drug Sensitivity in Cancer
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL553

Molecule Features

CHEMBL553 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Epidermal growth factor receptor erbB1 inhibitor Epidermal growth factor receptor erbB1 DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
CarcinomaD002277EFO:0000313carcinoma3ClinicalTrials
ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma3ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000349clear cell renal carcinoma1ClinicalTrials
Head and Neck NeoplasmsD006258EFO:0006859head and neck malignant neoplasia3ClinicalTrials
ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials
ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000681renal cell carcinoma2ClinicalTrials
ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma3ClinicalTrials
ClinicalTrials
GlioblastomaD005909EFO:0000519glioblastoma multiforme2ClinicalTrials
ClinicalTrials
NeoplasmsD009369EFO:0000311cancer4ClinicalTrials
ClinicalTrials
Neoplasms, Germ Cell and EmbryonalD009373EFO:0000514germ cell tumor2ClinicalTrials
ThymomaD013945EFO:1000581Thymoma2ClinicalTrials
Endometrial NeoplasmsD016889EFO:0004230endometrial neoplasm2ClinicalTrials
MeningiomaD008579Orphanet:2495Meningioma1ClinicalTrials
Esophageal NeoplasmsD004938EFO:0002916esophageal carcinoma3ClinicalTrials
ClinicalTrials
Hemorrhagic Fever, EbolaD019142EFO:0007243Ebola hemorrhagic fever1ClinicalTrials
PsoriasisD011565EFO:0000676psoriasis2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000640papillary renal cell carcinoma2ClinicalTrials
Uterine Cervical NeoplasmsD002583EFO:0001061cervical carcinoma1ClinicalTrials
Biliary Tract NeoplasmsD001661EFO:0003891biliary tract neoplasm2ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000181head and neck squamous cell carcinoma3ClinicalTrials
ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000707squamous cell carcinoma3ClinicalTrials
GliomaD005910EFO:0000326central nervous system cancer2ClinicalTrials
ClinicalTrials
Hepatitis C, ChronicD019698EFO:0004220Chronic Hepatitis C infection1ClinicalTrials
LeukemiaD007938EFO:0000565leukemia2ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma3ClinicalTrials
ClinicalTrials
Myelodysplastic SyndromesD009190EFO:0000198myelodysplastic syndrome2ClinicalTrials
Nasopharyngeal NeoplasmsD009303EFO:0004252nasopharyngeal neoplasm2ClinicalTrials
OligodendrogliomaD009837EFO:0000630oligoastrocytoma1ClinicalTrials
ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000708squamous cell lung carcinoma2ClinicalTrials
SarcomaD012509EFO:0000691sarcoma2ClinicalTrials
Adenomatous Polyposis ColiD011125Orphanet:733Familial adenomatous polyposis2ClinicalTrials
ClinicalTrials
AstrocytomaD001254EFO:0002499anaplastic astrocytoma1ClinicalTrials
ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma2ClinicalTrials
ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
ClinicalTrials
OligodendrogliomaD009837EFO:0002501anaplastic oligodendroglioma1ClinicalTrials
ClinicalTrials
Triple Negative Breast NeoplasmsD064726EFO:0005537triple-negative breast cancer2ClinicalTrials
Adenocarcinoma, Bronchiolo-AlveolarD002282EFO:0000308bronchoalveolar adenocarcinoma2ClinicalTrials
ClinicalTrials
Ovarian NeoplasmsD010051EFO:0001075ovarian carcinoma2ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0003860pancreatic neoplasm3ClinicalTrials
Skin NeoplasmsD012878EFO:0004198skin neoplasm2ClinicalTrials
EpendymomaD004806EFO:1000028ependymoma2ClinicalTrials
GliosarcomaD018316EFO:1001465gliosarcoma2ClinicalTrials
ClinicalTrials
Ovarian NeoplasmsD010051EFO:0003893ovarian neoplasm2ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma3ClinicalTrials
ClinicalTrials
Polycythemia VeraD011087EFO:0002429polycythemia vera2ClinicalTrials
Rectal NeoplasmsD012004EFO:1000657rectum cancer2ClinicalTrials
ClinicalTrials
Brain NeoplasmsD001932EFO:0003833brain neoplasm2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0002890renal carcinoma2ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma3ClinicalTrials
ClinicalTrials
Carcinoma, Large CellD018287EFO:0003050large cell lung carcinoma3ClinicalTrials
ClinicalTrials
DiseaseD004194EFO:0000408disease1ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
Mouth NeoplasmsD009062EFO:0003868mouth neoplasm3ClinicalTrials
Urinary Bladder NeoplasmsD001749EFO:0000292bladder carcinoma2ClinicalTrials
ClinicalTrials
MelanomaD008545EFO:0000756melanoma2ClinicalTrials
MesotheliomaD008654EFO:0005567malignant peritoneal mesothelioma2ClinicalTrials

Clinical Data

ClinicalTrials.gov ERLOTINIB
The Cochrane Collaboration ERLOTINIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL553. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL203 Epidermal growth factor receptor erbB1 Homo sapiens 1.000
CHEMBL1824 Receptor protein-tyrosine kinase erbB-2 Homo sapiens 1.000
CHEMBL3009 Receptor protein-tyrosine kinase erbB-4 Homo sapiens 1.000
CHEMBL2068 Ephrin type-A receptor 2 Homo sapiens 1.000
CHEMBL5147 Ephrin type-B receptor 4 Homo sapiens 1.000
CHEMBL279 Vascular endothelial growth factor receptor 2 Homo sapiens 1.000
CHEMBL2041 Tyrosine-protein kinase receptor RET Homo sapiens 1.000
CHEMBL1913 Platelet-derived growth factor receptor beta Homo sapiens 1.000
CHEMBL267 Tyrosine-protein kinase SRC Homo sapiens 1.000
CHEMBL4718 MAP kinase-interacting serine/threonine-protein kinase MNK1 Homo sapiens 1.000
CHEMBL1868 Vascular endothelial growth factor receptor 1 Homo sapiens 1.000
CHEMBL4722 Serine/threonine-protein kinase Aurora-A Homo sapiens 1.000
CHEMBL5260 Serine/threonine-protein kinase TNNI3K Homo sapiens 1.000
CHEMBL2185 Serine/threonine-protein kinase Aurora-B Homo sapiens 1.000
CHEMBL3905 Tyrosine-protein kinase Lyn Homo sapiens 1.000
CHEMBL4948 Dual specificity mitogen-activated protein kinase kinase 5 Homo sapiens 0.999
CHEMBL5319 Epithelial discoidin domain-containing receptor 1 Homo sapiens 0.998
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 0.998
CHEMBL6191 SPS1/STE20-related protein kinase YSK4 Homo sapiens 0.997
CHEMBL4202 Serine/threonine-protein kinase 2 Homo sapiens 0.997



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL203 Epidermal growth factor receptor erbB1 Homo sapiens 1.000
CHEMBL1824 Receptor protein-tyrosine kinase erbB-2 Homo sapiens 1.000
CHEMBL3009 Receptor protein-tyrosine kinase erbB-4 Homo sapiens 1.000
CHEMBL5147 Ephrin type-B receptor 4 Homo sapiens 1.000
CHEMBL2068 Ephrin type-A receptor 2 Homo sapiens 1.000
CHEMBL1913 Platelet-derived growth factor receptor beta Homo sapiens 1.000
CHEMBL279 Vascular endothelial growth factor receptor 2 Homo sapiens 1.000
CHEMBL2041 Tyrosine-protein kinase receptor RET Homo sapiens 1.000
CHEMBL267 Tyrosine-protein kinase SRC Homo sapiens 1.000
CHEMBL1868 Vascular endothelial growth factor receptor 1 Homo sapiens 1.000
CHEMBL4718 MAP kinase-interacting serine/threonine-protein kinase MNK1 Homo sapiens 1.000
CHEMBL4722 Serine/threonine-protein kinase Aurora-A Homo sapiens 1.000
CHEMBL5260 Serine/threonine-protein kinase TNNI3K Homo sapiens 1.000
CHEMBL1955 Vascular endothelial growth factor receptor 3 Homo sapiens 1.000
CHEMBL4948 Dual specificity mitogen-activated protein kinase kinase 5 Homo sapiens 1.000
CHEMBL3981 Serine/threonine-protein kinase 10 Homo sapiens 1.000
CHEMBL2185 Serine/threonine-protein kinase Aurora-B Homo sapiens 1.000
CHEMBL2634 Tyrosine-protein kinase CSK Homo sapiens 1.000
CHEMBL5014 Serine/threonine-protein kinase RIPK2 Homo sapiens 1.000
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
393.4 393.1689 3.41 10 74.73 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 1 0 7 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 5.32 3.03 3.03 3 29 0.42

Structural Alerts

There are 3 structural alerts for CHEMBL553. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE03 - erlotinib

ChemSpider ChemSpider:AAKJLRGGTJKAMG-UHFFFAOYSA-N
DailyMed erlotinib hydrochloride
PubChem SID: 103905339 SID: 124893165 SID: 124893166 SID: 144205755 SID: 170465434 SID: 26757996 SID: 50100099 SID: 85267493
Wikipedia Erlotinib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL553



ACToR 183321-74-6
BindingDB 5446
Brenda 50296 6877 127378
ChEBI 114785
ChemicalBook CB9285914
DrugBank DB00530
DrugCentral 1045
eMolecules 901844
EPA CompTox Dashboard DTXSID8046454
FDA SRS J4T82NDH7E
Guide to Pharmacology 4920
Human Metabolome Database HMDB0014671
IBM Patent System 498C9D856AD2E4B777A4BE26A9383BFB
LINCS LSM-1097
Mcule MCULE-7764565391
MolPort MolPort-003-847-084
Nikkaji J910.423B
PDBe AQ4
PharmGKB PA134687924
PubChem 176870
PubChem: Thomson Pharma 14878691
SureChEMBL SCHEMBL8413
ZINC ZINC000001546066

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/AAKJLRGGTJKAMG-UHFFFAOYSA-N spacer
spacer